Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Identified important optimization features for its platform to mitigate PFO risks in current and future programs
Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated IND-enabling studies in 2023
Related news for (SGTX)
- SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. – SGTX
- SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. – SGTX